Kobayashi Pharmaceutical 관리

관리 기준 확인 1/4

현재 CEO에 대한 정보가 충분하지 않습니다.

주요 정보

Satoshi Yamane

최고 경영자

n/a

총 보상

CEO 급여 비율	n/a
CEO 임기	less than a year
CEO 소유권	0.01%
경영진 평균 재임 기간	데이터 없음
이사회 평균 재임 기간	6yrs

최근 관리 업데이트

Recent updates

CEO

Satoshi Yamane (64 yo)

less than a year

테뉴어

Mr. Satoshi Yamane is President of Kobayashi Pharmaceutical Co. Ltd. from July 2024 and serves as Senior MD & Head of Sustainability Management Headquarters since January 2024. He was General Manager of Gr...

이사회 구성원

이름	위치	테뉴어	보상	소유권
Satoshi Yamane	President	18.4yrs	데이터 없음	0.011% € 284.2k
Kunio Ito	Independent Outside Director	11.4yrs	데이터 없음	데이터 없음
Yoshiro Katae	Independent Outside Director	2.7yrs	데이터 없음	데이터 없음
Yoko Hatta	Outside Audit & Supervisory Board Member	9.4yrs	데이터 없음	데이터 없음
Kaori Sasaki	Independent Outside Director	8.4yrs	데이터 없음	데이터 없음
Ikeaki Ariizumi	Independent Outside Director	2.7yrs	데이터 없음	데이터 없음
Takashi Kawanishi	Full-time Audit & Supervisory Board Member	3.7yrs	데이터 없음	데이터 없음
Sumio Moriwaki	Outside Audit & Supervisory Board Member	1.7yrs	데이터 없음	데이터 없음

6.0yrs

평균 재임 기간

66yo

평균 연령

경험이 풍부한 이사회: KOY 의 이사회는 경험(평균 재직 기간 6 년)으로 간주됩니다.

Kobayashi Pharmaceutical 관리

관리 기준 확인 1/4

주요 정보

최근 관리 업데이트

Kobayashi Pharmaceutical Co., Ltd., Annual General Meeting, Mar 28, 2024

Kobayashi Pharmaceutical Co., Ltd., Annual General Meeting, Mar 30, 2023

Kobayashi Pharmaceutical Co., Ltd., Annual General Meeting, Mar 26, 2021

Recent updates

Third quarter 2024 earnings released: EPS: JP¥52.57 (vs JP¥100 in 3Q 2023)

Kobayashi Pharmaceutical Co., Ltd. to Report Q3, 2024 Results on Nov 08, 2024

New minor risk - Profit margin trend

Kobayashi Pharmaceutical Co., Ltd. to Report Q2, 2024 Results on Aug 08, 2024

Upcoming dividend of JP¥44.00 per share

First quarter 2024 earnings released: EPS: JP¥13.13 (vs JP¥47.43 in 1Q 2023)

Kobayashi Pharmaceutical Co., Ltd. to Report Q1, 2024 Results on May 10, 2024

New minor risk - Share price stability

Now 20% overvalued

Kobayashi Pharmaceutical Co., Ltd., Annual General Meeting, Mar 28, 2024

Full year 2023 earnings released: EPS: JP¥268 (vs JP¥260 in FY 2022)

Kobayashi Pharmaceutical Co., Ltd. to Report Fiscal Year 2023 Results on Feb 09, 2024

Upcoming dividend of JP¥53.00 per share at 1.5% yield

New minor risk - Shareholder dilution

Kobayashi Pharmaceutical Co., Ltd. (TSE:4967) announces an Equity Buyback for 1,924,600 shares, representing 2.53% for ¥11,999.88 million.

Third quarter 2023 earnings released: EPS: JP¥100 (vs JP¥88.00 in 3Q 2022)

Kobayashi Pharmaceutical Co., Ltd. (TSE:4967) acquired Focus Consumer Healthcare, LLC.

Second quarter 2023 earnings released: EPS: JP¥55.91 (vs JP¥54.70 in 2Q 2022)

Upcoming dividend of JP¥39.00 per share at 1.1% yield

First quarter 2023 earnings released: EPS: JP¥47.43 (vs JP¥44.86 in 1Q 2022)

Full year 2022 earnings released: EPS: JP¥260 (vs JP¥252 in FY 2021)

Kobayashi Pharmaceutical Co., Ltd., Annual General Meeting, Mar 30, 2023

Upcoming dividend of JP¥47.00 per share

Kobayashi Pharmaceutical Co., Ltd. to Report Q1, 2023 Results on May 10, 2023

Third quarter 2022 earnings released: EPS: JP¥88.00 (vs JP¥89.58 in 3Q 2021)

Third quarter 2022 earnings released: EPS: JP¥87.99 (vs JP¥89.58 in 3Q 2021)

Kobayashi Pharmaceutical Co., Ltd. (TSE:4967) announces an Equity Buyback for 1,265,800 shares, representing 1.64% for ¥9,999.82 million.

Second quarter 2022 earnings released: EPS: JP¥54.70 (vs JP¥54.41 in 2Q 2021)

Upcoming dividend of JP¥38.00 per share

First quarter 2022 earnings released: EPS: JP¥44.86 (vs JP¥46.42 in 1Q 2021)

Full year 2021 earnings: EPS in line with expectations, revenues disappoint

Full year 2021 earnings: EPS in line with expectations, revenues disappoint

Upcoming dividend of JP¥44.00 per share

Third quarter 2021 earnings released: EPS JP¥89.58 (vs JP¥90.07 in 3Q 2020)

Second quarter 2021 earnings released: EPS JP¥54.41 (vs JP¥57.27 in 2Q 2020)

Upcoming dividend of JP¥35.00 per share

First quarter 2021 earnings released: EPS JP¥46.42 (vs JP¥47.87 in 1Q 2020)

Kobayashi Pharmaceutical Co., Ltd. to Report Q1, 2021 Results on Apr 27, 2021

New 90-day low: €83.50

New 90-day low: €85.00

Kobayashi Pharmaceutical Co., Ltd., Annual General Meeting, Mar 26, 2021

Full year 2020 earnings released: EPS JP¥246 (vs JP¥244 in FY 2019)

Revenue misses expectations

Kobayashi Pharmaceutical Co., Ltd. to Report Fiscal Year 2020 Results on Feb 01, 2021

New 90-day high: €104

Upcoming Dividend of JP¥41.00 Per Share

New 90-day high: €99.50

New 90-day high: €92.00

Revenue misses expectations

Third quarter 2020 earnings released: EPS JP¥90.07

New 90-day high: €83.50

Third quarter earnings released

Third-quarter earnings released: Revenue misses expectations

New 90-day high: €83.00

Kobayashi Pharmaceutical Co., Ltd. (TSE:4967) signed an contract to acquire Alva-Amco Pharmacal Companies, Inc. from Trusts all owned by the founder's family for approximately $110 million.

New 90-day high: €81.00

First half earnings released

New 90-day low - €73.00

CEO

테뉴어

이사회 구성원

평균 재임 기간

평균 연령